Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE: AT-007 in SORD Deficiency
NCT05397665Phase 3Completed
- Sponsor
- Applied Therapeutics, Inc.
- Start
- Jan 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in Sorbitol Dehydrogenase Deficiency comparing AT-007 with Placebo (2 arms). Primary endpoints: 10-meter walk-run test at 24 months and Blood sorbitol levels at 3 months. Started Jan 2022; status: completed.
02
Drugs
govorestat
03
Conditions
Sorbitol Dehydrogenase Deficiency
Beyond the preview
Go deeper on NCT05397665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05397665.